TickerGuard
Buy Day today: Good (67) Broad market participation · no major macro event

Vertex Pharmaceuticals Inc (VRTX)

Healthcare Biotechnology
470.70 $
-1.3% vs. previous close
Closing price · As of: 3. Aug 2026

Who owns Vertex Pharmaceuticals Inc (VRTX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.7% of the shares are freely tradable; institutional investors hold 98.0%.

Ownership Structure

Institutional ownership
98.0%
Insiders
0.2%
Float
99.7%
Short % of float
2.2%
Shares Outstanding
254Mio.

Largest Shareholders

Institutions

Institutions VRTX
Name Stake (%) Shares Change (%) Date
Capital World Investors 10.00 25,368,124 -0.6 03/31/2026
BlackRock Inc 9.44 23,969,517 +0.9 03/31/2026
Capital Research Global Investors 8.32 21,125,964 +22.0 03/31/2026
Vanguard Capital Management, LLC 6.51 16,512,810 +0.0 03/31/2026
State Street Corp 4.62 11,730,139 +0.3 03/31/2026
Amvescap Plc. 3.11 7,892,611 +0.5 03/31/2026
JPMorgan Chase & Co 2.77 7,033,156 +16.5 03/31/2026

Funds

Funds VRTX
Name Stake (%) Shares Change (%) Date
American Funds Growth Fd of Amer A 4.94 12,542,510 -10.0 06/30/2026
Capital Group Growth Fnd of Amer Comp 4.94 12,542,510 -10.0 06/30/2026
Vanguard Morn Total Stk Mkt Idx Investor 3.18 8,059,531 -0.3 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
21. Jul 2026 Tatsis Ourania EVP, Chief Reg. & Quality Off. Other 8,251 0.00
21. Jul 2026 Sachdev Amit EVP Chief Patient & Ext Af Off Other 8,251 0.00

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?